Table I.

PNH patient and thromboembolism characteristics.

Patient Group	Patients treated with C5 inhibitor monotherapy (n=18)	Patients treated with C5 inhibitor and indefinite anticoagulation (n=4)
History of aplastic anemia, no.	7	0
Sex, no.
Male	11	1
Female	7	3
Race
Caucasian	14	1
Black	4	3
Median age at PNH diagnosis (range)	23.5 years (10–50)	41 years (36–61)
Median PNH granulocyte clone at TE diagnosis (range)	96% (73–100)	87.8% (78–99)
Median disease duration pre-C5 inhibition (range)	4 years (0–14)	3.5 years (0.5–8)
Median time on anti-C5 treatment (range)	10 years (0.5–15)	9.5 years (5–13)
Median time on anticoagulation (range)	4 months (0–11 years)	9 years (4–19)
Location of TE events prior to C5 inhibition, no. †
DVT	1	1
pulmonary embolism	1	1
abdominal vein	11	2
dermal	1	-
small bowel	3	-
cerebrovascular	3	2
IVC	1	-
renal vein	2	-
ureter	1	-
tonsillar	1	-
Location of TE events on C5 inhibitor, no.
DVT	2‡	1§
pulmonary embolism	-	1

^†28/31 TE events occurred not on anticoagulation.

^‡Not on concurrent anticoagulation. Two lower extremity deep vein thromboses (DVT) around major surgeries, hip replacement and liver transplant, respectively.

^§1 bilateral DVT attributed to uterine compression.